<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561741</url>
  </required_header>
  <id_info>
    <org_study_id>COV15010370</org_study_id>
    <nct_id>NCT02561741</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions</brief_title>
  <official_title>An Open-Label, Randomized, Single-Dose, Three-Period Crossover Study to Evaluate the Pharmacokinetics, Bioavailability, and Safety of 3 Tablets of COV155 Administered in Normal, Healthy Subjects Under Fed (High- and Low-Fat Meal) and Fasted Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, single dose, open-label, randomized, 3-period, 6-sequence, crossover study&#xD;
      conducted in normal healthy subjects to evaluate the effect of a high- and low-fat meal on&#xD;
      the pharmacokinetics (PK), bioavailability (BA), and safety of COV155.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>48 hours</time_frame>
    <description>To evaluate the effect of food on the pharmacokinetics and bioavailability of COV155 following administration of the formulation given as 3 tablets in healthy subjects under fasting and fed (high- and low-fat) conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>48 hours</time_frame>
    <description>To evaluate the effect of food on the pharmacokinetics and bioavailability of COV155 following administration of the formulation given as 3 tablets in healthy subjects under fasting and fed (high- and low-fat) conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to achieve the maximum observed plasma concentration (Tmax)</measure>
    <time_frame>48 hours</time_frame>
    <description>To evaluate the effect of food on the pharmacokinetics and bioavailability of COV155 following administration of the formulation given as 3 tablets in healthy subjects under fasting and fed (high- and low-fat) conditions</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>COV155</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COV155</intervention_name>
    <description>COV155 tablets</description>
    <arm_group_label>COV155</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and/or non-pregnant, non-lactating or postmenopausal females, between 18 and 55&#xD;
             years of age with a body mass index ≥ 19 and ≤ 30 kg/m2.&#xD;
&#xD;
          2. All subjects biologically capable of having children must agree and commit to the use&#xD;
             acceptable method(s) of birth control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ECG abnormalities or lab values greater than 2 times the upper limit of normal.&#xD;
&#xD;
          2. Positive test results for human immunodeficiency virus (HIV), hepatitis B (HBsAg), or&#xD;
             hepatitis C (IgG).&#xD;
&#xD;
          3. Positive urine test results for drugs of abuse or history of drug/alcohol abuse.&#xD;
&#xD;
          4. Use of marijuana, illicit drugs or nicotine-containing products.&#xD;
&#xD;
          5. Donated or had significant loss of whole blood.&#xD;
&#xD;
          6. Taken any prescription or nonprescription drugs, vitamins, minerals, or dietary/herbal&#xD;
             supplements.&#xD;
&#xD;
          7. History of abdominal and/or pelvic surgery, cholecystectomy, gastric bypass or gastric&#xD;
             band surgery, or cardiothoracic surgery.&#xD;
&#xD;
          8. History of anxiety, tension, agitation, psychiatric disorders, psychosis, or&#xD;
             depression requiring hospitalization, psychotherapy, and/or medication.&#xD;
&#xD;
          9. History of acute or chronic gastrointestinal disease or any condition that may&#xD;
             interfere with the absorption, distribution, metabolism or excretion of the study&#xD;
             treatment.&#xD;
&#xD;
         10. History of seizures or diagnosis of epilepsy or other seizure disorder.&#xD;
&#xD;
         11. History or laboratory evidence of bleeding or clotting disorder or condition.&#xD;
&#xD;
         12. History or laboratory evidence of malignancy, stroke, diabetes, cardiac, renal, liver,&#xD;
             and chronic pulmonary disease.&#xD;
&#xD;
         13. Have or have a history of hay fever or seasonal allergies requiring over-the-counter&#xD;
             or prescription medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>September 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2015</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

